Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : IMDS nasdaq bulletin board -- Ignore unavailable to you. Want to Upgrade?

To: Benoit Desrochers who wrote (1599)	8/19/1998 9:06:00 PM
From: Dan O	Read Replies (1) \| Respond to of 4122

This is from the FDA site: FDA Enforcement Report The FDA Enforcement Report is published weekly by the Food and Drug Administration, U.S. Public Health Service, Department of Health and Human Services. It contains information on actions taken in connection with agency regulatory activities. ------------------------------------------------------------------------ ENFORCE 08/10/1994 PRODUCT Breast Transilluminator, Lintroscan> Model 200G used for the detection of changes in the breast. Recall #Z-1184-4. CODE Serial numbers: 080792-02, 082492-03, 082492-04, 01092-05, 01092-06, 01092-07. MANUFACTURER <Lintronics Technologies, Inc., Tampa, Florida. RECALLED BY Manufacturer, by telephone mid November 1993. Firm- initiated recall complete. DISTRIBUTION Illinois, Ohio, Georgia, Florida, Virginia. QUANTITY 6 units. REASON Product labeling fails to bear adequate directions for use. FDA has concluded that transillumination for the examination of the breast is not clinically effective for the diagnosis or detection of breast cancer or other breast abnormalities or conditions. Obviously, I have no idea if Grable was behind Lintronics